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Abstract. 
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare disease with high fatality. 
It can be genetic, or it can be associated with infection, malignancy or autoimmune disorders. 
Cases of nasopharyngeal carcinoma (NPC) associated with HLH are rare. 
Case Report: A 56 year-old man with recurrent NPC with metastases had concurrent HLH. 
The patient presented with fever, splenomegaly, cytopenia in three lineages, elevated ferritin, 
elevated liver transaminases, hyperbilirubinemia, and hemophagocytosis in bone marrow. He 
also had a very high serum Epstein-Barr (EB) viral load. We diagnosed HLH in this patient, be-
lieving it to be associated with either EB virus or NPC. Following treatment with etoposide, 
cisplatin and intravenous immunoglobulin, the levels of liver transaminases and bilirubin de-
creased, but the patient’s pancytopenia did not improve before he died of aspiration pneumonia 
6 months after the diagnosis of NPC.  
Conclusions: HLH is a disease with high fatality. Whenever there is a degree of clinical suspi-
cion for HLH, etoposide-based chemotherapy should be started as soon as possible, and the 
underlying causes of the disease should be treated. We report this patient with NPC and HLH, 
which can be associated with either EBV or NPC. We treated both etiologies, and the patient’s 
symptoms and liver function improved. The interactions between EBV, NPC, and HLH are in-
teresting and merit further investigation. 
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中文摘要 
背景：嗜血性淋巴組織球血症是一個少見致命率高的疾病。先天基因缺陷、感染、惡性
血液疾病或腫瘤、或自體免疫疾病都可能導致嗜血性淋巴組織球血症的發生。與鼻咽癌
相關的嗜血性淋巴組織球血症的病例報告很少見。 
病例報告：56 歲男性病例有復發且多處發生轉移的鼻咽癌且後續病發嗜血性淋巴組織球
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血症。病患發生了持續發燒、脾臟腫大、血球減少、血中鐵蛋白及肝指數上升、黃疸及
骨髓抹片中發現嗜血性淋巴組織球。他同時併有極高的血中 Epstein-Barr (EB)病毒量。他
被我們診斷為 EB 病毒或鼻咽癌相關之嗜血性淋巴組織球血症。我們使用 etoposide、
cisplatin 及靜脈免疫球蛋白注射治療。雖然最後病患在血球數開始恢復前因吸入性肺炎過
世，但在過世前肝指數及黃疸卻逐漸改善。 
結論：嗜血性淋巴組織球血症是個高致死性的疾病。醫師於臨床上懷疑病患罹患此症，
必須儘快給予 etoposide 為基底的化學治療，並同時治療導致嗜血性淋巴組織球血症的病
因。在本病例報告中，病患的嗜血性淋巴組織球血症可能與 EB 病毒或鼻咽癌相關，因此
我們同時治療兩個病因，病患的症狀因此改善。嗜血性淋巴組織球血症與 EB 病毒和鼻咽
癌之間的相關性是後續值得探討的議題。 
 
關鍵字: 鼻咽癌、嗜血性淋巴組織球血症、EB 病毒 
 
INTRODUCTION 
Hemophagocytic lymphohistiocytosis (HLH) is a 
disease with high fatality characterized by immune 
activation and extreme inflammation leading to multi-
ple organ failure. Familial HLH is caused by a genetic 
disorder and is often triggered by viral infection. Spo-
radic HLH is usually associated with infection (typi-
cally viral, commonly Epstein–Barr virus (EBV)), 
malignancy, or autoimmune disorders. We report in 
this communication a case of recurrent nasopharynge-
al carcinoma (NPC) with metastases with concurrent 
HLH. 
 
CASE REPORT 
The patient was a 56 year-old man with no signif-
icant medical history who presented with progressive 
left neck masses in the course of one month. Cytology 
of fine needle aspiration of the neck mass revealed 
metastatic poorly differentiated carcinoma. Magnetic 
resonance imaging of the head and neck revealed a 
tumor located in the nasopharynx. Core needle biopsy 
of this nasopharyngeal tumor revealed an undifferen-
tiated non-keratinizing carcinoma. Immunohistochem- 
ical stain of EBV-encoded RNA (EBER) was diffusely 
positive. NPC was diagnosed. Positron emission to-
mography (PET) revealed locally advanced disease 
without distant metastasis. The initial tumor stage was 
determined to be cT1N3bM0, stage IVB. The patient 
received induction chemotherapy with cisplatin and 
5-fluorouracil (5-FU) followed by cisplatin-based 
concomitant chemoradiotherapy. Two weeks after 
completing radiotherapy, the patient suffered from 
progressive and severe low back pain. A lumbosacral 
MRI revealed diffuse nodular lesions in the T-L-S 
spine and pelvic cage with abnormal signal and en-
hancement, and a bone scan revealed multiple meta-
static bone lesions involving the axial and appendicu-
lar skeleton. Abdominal ultrasonography revealed one 
1.23 × 0.98 cm heterogeneous hypoechoic lesion at S6 
of the liver. Recurrent NPC with diffuse bony metas-
tases and liver metastasis was suspected. The patient 
received weekly high-dose 5-FU and Leucovorin (LV). 
However, intermittent fever and progressive pancyto-
penia developed, with a white blood count of 2600/uL, 
a platelet count of 45K/uL, and a hemoglobin level of 
8.0 g/dL. Bone marrow aspiration and biopsy revealed 
diffuse cancer nests in the bone marrow. EBER was 
also diffusely positive. The patient’s pancytopenia 
could be explained by the diffuse bone marrow-   
occupying tumor cells. Liver transaminases (SGOT/ 
SGPT) and total bilirubin gradually increased to 
1089/437 U/L and 13 mg/dL, respectively, and yet 
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Figure 1. Liu’s stain, 1000X. Hemophagocytes: platelets in histiocytes 
 
 
liver ultrasonography revealed only three heterogene-
ous hypoechoic lesions (up to 1.2 cm in diameter) and 
mild splenomegaly. Laboratory data were negative for 
anti-HAV IgM, HBsAg and all markers of autoim-
mune hepatitis with the exception of a positive result 
for anti-HCV, but HCV viral load was undetectable. 
The patient’s ferritin level (15945 ng/mL) and TG 
level (165 mg/dL) were both elevated. Bone marrow 
aspiration from the sternum revealed some hemopha-
gocytes (Figure 1). According to the diagnostic criteria 
for HLH presented in the HLH-2004 trial, our patient 
fulfilled diagnostic criteria for HLH by having fever, 
splenomegaly, cytopenia in three lineages, elevated 
ferritin, and hemophagocytosis in the bone marrow. 
By these criteria, we diagnosed HLH in this patient 
(Table 1) [1,2]. The patient’s serum EBV viral load 
was found to be significantly elevated at 4275000 
copies/mL. This patient had an elevated EBV load and 
EBV in tumor tissues, which would point to EBV as 
an etiology for the HLH, but he also had NPC as a 
possible etiology for the HLH. According to classifi-
cation criteria for the determination of EBV infection 
as the primary process causing HLH, (Table 2) [3] this 
patient’s score was 3, representing probable EBV-  
associated HLH.   
The patient was treated with intravenous immuno-
globulin (IVIG) (2 gm/kg) and chemotherapy using 
etoposide and cisplatin (etoposide 50 mg/m2 per day 
for days 1-3; cisplatin 70 mg/m2 on day 1). Following 
treatment, the patient’s EBV viral load decreased sig-
nificantly to 312500 copies/mL, ferritin decreased to 
11050 ng/mL, SGPT decreased to 64 U/L, and total 
bilirubin peaked at 34 mg/dL before decreasing to 
24.6 mg/dL. His low back pain also improved. How-
ever, the patient’s pancytopenia did not improve be-
fore he died from aspiration pneumonia. 
 
DISCUSSION 
HLH can be classified as familial HLH or sporadic 
HLH. Both conditions are associated with a lympho-
cyte cytotoxic function defect and will lead to clinical 
symptoms and signs of severe inflammation. Clinical 
symptoms include fever, hepatosplenomegaly, jaun-
dice, lymphadenopathy, rash, seizure, and focal neu-
rologic deficits. Laboratory findings of HLH include 
cytopenia, elevated SGOT and SGPT, hyperbiliru-
binemia, elevated ferritin, elevated triglyceride, eleva-
tion of multiple cytokines (for example, INF-γ, TNF-α, 
IL6, or IL10.), and decreased fibrinogen. Histological 
examination of the bone marrow, spleen, or lymph 
nodes may show infiltration of lymphocytes or mac-
rophages and hemophagocytosis [4]. Familial HLH is 
a genetic disorder and typically has a clear pattern of 
familial inheritance [1]. Familial HLH is caused by 
mutations of perforin genes and defects of lymphocyte 
cytotoxic function, and it is usually triggered by a viral 
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infection. This proposed etiology has been proved 
using an animal model [4]. In a LCMV (lymphocytic 
choriomeningitic virus)-infected and perforin gene 
knockout (pfp -/-) model, pfp -/- CD8+ T cells lose their 
perforin-dependent ability to kill virally infected anti-
gen presenting cells, which induces extreme immune 
activation. Sporadic HLH is usually triggered by in-
fection – in particular by EBV or herpes simplex virus 
(HSV) – malignancy, or rheumatologic disorders [1]. 
A strong clinical suspicion and clinical criteria are 
important in diagnosing HLH. Because hemophago-
cytosis is neither sensitive nor specific for HLH [1], 
doctors should not delay the diagnosis of HLH due to 
the absence of evident hemophagocytosis. 
Malignancy-associated HLH occurs most often 
with lymphomas or leukemias of the T or NK cell lin-
eages, less often with B cell leukemia, and rarely with 
solid tumors. There are only a few case reports of 
HLH associated with medulloblastoma, Ewing sar-
coma, or mediastinal germ cell tumors [1]. Rare cases 
have been reported of HLH associated with NPC [5]. 
EBV-associated HLH (EBV-HLH) has a relatively 
high incidence in Asian countries, which might be due 
to the presence of a pathogenic EBV strain. In such 
cases, the disease has been associated primarily with 
EBV reactivation. During primary infection with EBV, 
EBV infects and replicates in B cells. However, in 
cases of EBV-HLH, EBV infects CD8+ cells, 
EBV-specific cytotoxic T cells become inadequate, 
and NK-T cell dysfunction and HLH occur [6]. The 
EBV viral load is usually much higher in patients with 
EBV-HLH (>1000–1000000 copies/μg of PBMC 
DNA; PBMC-peripheral blood mononuclear cell) than 
it is in patients with infectious mononucleosis 
(100–1000 copies/μg of PBMC DNA). Measuring the 
EBV viral load at four months after treatment for 
HLH can help determine the response to treatment and 
has a prognostic value as well [6]. There are accepted 
scoring criteria for the determination of EBV infection 
as the primary process causing HLH. The scoring sys-
tem criteria include the level of HBV viral load, the 
duration of EBV viremia, the presence of EBV in tis-
sues, evidence of exposure to other viruses associated 
with HLH, and alternative etiologies for HLH (Table 2) 
[3]. The patient in our case met the clinical criteria for 
HLH, and it was thought that this was likely a case 
Table 1. Diagnostic criteria for HLH used in the HLH-2004 trial: the diagnosis is made if fulfilled with criteria I 
or with five or more of the eight criteria listed in criteria II. [1] 
I. Genetic mutations of PRF1, UNC13D, Munc18-2, Rab27a, STX11, SH2D1A, or BIRC4 
II. The eight clinical criteria: 
A. Fever ≧ 38.5°C 
B. Splenomegaly 
C. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood) 
Hemoglobin < 9 g/dL 
Platelets < 100 X 103/mL 
Neutrophils < 1 X 103/mL 
D. Hypertriglyceridemia (fasting, > 265 mg/dL) and/or hypofibrinogenemia 
(< 150 mg/dL) 
E. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver 
F. Low or absent NK-cell activity 
G. Ferritin > 500 ng/mL 
H. Elevated sCD25 
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Table 2. Classification criteria for determination of EBV infection as the primary process causing HLH. [5] 
Parameter Points 
EBV load (PCR) <5,000 copies/ml 1 
EBV load (PCR) >5,000 copies/ml 2 
Duration of EBV viremia <1 month 1 
Duration of EBV viremia >1 month 2 
Presence of EBV in tissues 2 
Evidence (history, serologies, PCR) of exposure to other virus associated with HLH -1 
Alternative etiologies for HLH -1 
Definite: 6 points; Probable: 3-5 points; Possible: 1-2 points 
 
 
of EBV-HLH due to the high serum EBV viral load 
and the presence of EBV in tumor tissues. However, 
there remained questions as to whether EBV-HLH was 
the actual etiology of HLH in our patient. First, 
EBV-HLH occurs mostly in conjunction with a pri-
mary infection or a reactivation of EBV, but our pa-
tient had no symptoms or signs of acute infection such 
as sore throat, general lymphadenopathies, or atypical 
lymphocytes in the blood. The lack of immune pro-
files for EBV infection (for example VCA IgG, VCA 
IgM, EBNA IgG) and biopsies from lymph nodes or 
other lymphoreticular systems to prove EBV infection 
outside of tumor tissues precluded a definitive diag-
nosis or exclusion of EBV-HLH in our patient. Second, 
EBV actively infects cytotoxic T cells and NK cells, 
and ultimately leads to NK-T cell dysfunction in 
EBV-HLH. The virus remains in the lytic phase in this 
situation. However, in patients with NPC, EBV re-
mains in the latent phase and expresses EBER, 
EBNA-1, LMP-1, and LMP-2 proteins, which are re-
sponsible for tumorigenesis. In our patient’s tumor 
specimens, diffuse positivity for EBER was evident, 
so we concluded that EBV in our patient was in the 
latent phase. However, other studies have revealed 
that LMP-1 can up-regulate the TNF-α gene and lead 
to increased secretion from infected T lymphocytes in 
HBV-HLH [7]. Third, the serum EBV DNA load cor-
relates with stage, response to treatment, and likeli-
hood of relapse and survival among patients with ad-
vanced NPC [8], but it does not represent active EBV 
infection. In our patient, EBV viral load decreased 
after treatment with etoposide and cisplatin. This de-
crease may have been due to the success in treating 
the patient’s EBV-HLH, but it may also have resulted 
from treatment of the NPC with etoposide and cispla-
tin. Therefore, it is necessary to prove EBV infection 
in T lymphocytes, whether in the lytic or latent phase, 
in order to make a definitive diagnosis of EBV-HLH. 
We had some limitations in diagnosing EBV as the 
etiology of HLH in our patient, and we had several 
reasons to believe that NPC might instead be the eti-
ology of our patient’s HLH. The geographic distribu-
tion of patients with EBV-HLH is similar to the geo-
graphic distribution of patients with NPC, but only 
rare cases have been reported of patients with NPC 
and concurrent HLH. This suggests that EBV-HLH 
and NPC might be caused by the same pathogenic 
EBV strains but with different pathological mecha-
nisms. 
The standard treatment for HLH is an etopo-
side–based chemotherapy and treatment of the under-
lying triggers of HLH. For example, anti-viral agents, 
rituximab for EBV infection, and intravenous immu-
noglobulin are possible treatments for HLH with an 
underlying viral infection [1]. The HLH-94 protocol is 
a well-known etoposide-based regimen that incorpo-
rates dexamethasone in the induction phase and grad-
ually tapering doses of etoposide and dexamethasone 
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in the continuation phase. Intrathecal methotrexate is 
used if central nervous system involvement is evident. 
Cyclosporine A is used in the continuation phase [9]. 
Treatment according to the HLH-94 protocol leads to 
a complete remission rate of 50% and a 3-year overall 
survival rate of 55% [9]. The HLH-2004 protocol is 
modified from HLH-94 protocol in two ways: it calls 
for the upfront use of cyclosporine A during the in-
duction phase and for the added use of hydrocortisone 
to the intrathecal methotrexate. However, treatment 
according to the HLH-2004 protocol appears to cause 
an increase in the incidence of posterior reversible 
encephalopathy syndrome, which might be due to ma-
lignant hypertension caused by cyclosporine A. 
Treatment with antithymocyte globulin (ATG) com-
bined with methylprednisolone has also been tested in 
patients with familial HLH and has been reported to 
yield higher complete remission rates (82% remission 
rate with first-line ATG therapy and 50% remission 
rate with second-line ATG therapy) better than does 
treatment according to the HLH-94 protocol. However, 
the long-term outcome of HLH patients treated with 
ATG is not superior because of higher relapse rates 
associated with this treatment approach [10]. Hema-
topoietic stem cell transplantation is recommended for 
refractory, recurrent, and familial HLH, and for cases 
with central nervous system involvement. Many sal-
vage therapy treatments have also been tested, includ-
ing infliximab (a TNF-alpha antibody), daclizumab (a 
CD25 antibody), alemtuzumab (a CD52 antibody), 
anakinra (an IL1 receptor antagonist), vincristine, and 
anti-interferon gamma [1]. 
Among all cases of virus-associated HLH, those 
with EBV-HLH have the worst outcome. Early initia-
tion of etoposide-based chemotherapy is crucial. Late 
treatment (>4 weeks from diagnosis) is associated 
with a lower survival rate than is early treatment (≦4 
weeks from diagnosis) (p <0.01) [11]. 
 
CONCLUSIONS 
HLH is a disease with high fatality. Whenever 
there a degree of clinical suspicion for HLH, etopo-
side-based chemotherapy should be started as soon as 
possible and underlying causes of the disease should 
be treated. 
We report a case of a patient with NPC and HLH 
whose HLH was associated with both EBV and NPC. 
The geographic distribution of patients with 
EBV-HLH is similar to that of patients with NPC, but 
only rarely have cases been reported of NPC with 
concurrent HLH. This leads us to believe that 
EBV-HLH and NPC might be caused by the same 
pathogenic EBV strains but with different pathological 
mechanisms. The interactions between EBV, NPC, 
and HLH are interesting and merit further investiga-
tion. 
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